Skip to main content

Free Content Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Summary Purpose:

To compare the pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western adults, and to comparatively assess carisbamate safety and tolerability between the two populations. Methods:

An open-label study was conducted in 24 Japanese and 24 Caucasian healthy subjects. Subjects received a single oral dose of 250 mg carisbamate on day 1 followed by a 3-day washout period; twice-daily dosing of 250 mg carisbamate on days 5–8; subsequently, 500 mg on days 9–12 and a single dose of 500 mg on day 13. Plasma samples were collected for a pharmacokinetic analysis on days 1, 8, and 13. Plasma and urine samples were analyzed for carisbamate and its urinary metabolites by liquid-chromatography-mass-spectrometry. Results:

Following a single dose, carisbamate Cmax and area under the curve (AUC) geometric mean ratios were 16.4% and 28.8% higher in Japanese than in Caucasians, respectively; these differences were statistically significant and their 90% confidence intervals (CIs) fell outside of the 80–125% limits, which are considered not to be of clinical significance. With dose–body weight normalization, Cmax and AUC were similar in Japanese and Caucasian subjects and the 90% CIs were within the 80–125% boundaries. Carisbamate was well tolerated, and its mean oral clearance and half-life were similar in both groups, ranging from 35.1–41.4 ml/h/kg and 11.5–12.8 h. Discussion:

Carisbamate plasma exposure (AUC) and Cmax in Japanese subjects is ∼20–25% higher than in Caucasians due to a higher mg/kg dose. After body weight normalization, carisbamate pharmacokinetics was similar between Japanese and Caucasian subjects following single and multiple dosing, and showed the same dose proportionality.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Carisbamate; Japanese and Western healthy subjects; New antiepileptic drug; Pharmacokinetics; RWJ-333369

Document Type: Research Article

Affiliations: 1: Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan and Titusville, NJ, USA 2: Johnson & Johnson Pharmaceutical Research & Development, a Division of Janssen Pharmaceutica, NV, Beerse, Belgium

Publication date: 2009-08-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more